Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on July 28, 2016. The report announces the financial results for the fiscal quarter ended June 30, 2016. The full details of these results are contained in a press release furnished as Exhibit 99.1, which is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These specific metrics are referenced only as being contained within the attached press release (Exhibit 99.1), the text of which is not included in the provided input.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. It serves solely as a notification that results for the quarter ended June 30, 2016, have been issued.
Guidance, Outlook, and Risks
The report includes a standard disclaimer regarding forward-looking statements. These statements reflect management's current intentions, beliefs, and expectations but are not guarantees of future performance. The filing notes that actual results may differ materially due to risks, uncertainties, and assumptions, including those discussed in the Company's Annual Report on Form 10-K. The Company does not undertake an obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the correct registrant name is Oculus Innovative Sciences, Inc., as the input metadata incorrectly listed "Sonoma Pharmaceuticals, Inc."
- Locate and review Exhibit 99.1 (the press release) to obtain actual revenue, profit, and cash flow figures, as they are absent from the 8-K text.
- Review the most recent Form 10-K for a detailed list of risk factors referenced in the forward-looking statements disclaimer.
- Confirm the fiscal quarter end date is June 30, 2016.